

Wissenschaftliche Tätigkeit

Dissertation:

- 19.4.1991 Verleihung der Doktorwürde durch den Fachbereich Medizin der Universität Hamburg für die "Immunhistologische Untersuchung zur Expression von tumorassoziierten Antigenen, Wachstumsfaktorzepetoren, Histokompatibilitätsantigenen und Onkogenproteinen in Gewebe und Zellkultur von neoplastischem und nichtneoplastischem Pankreas". Betreuung durch Prof. G. Klöppel (Institut für Pathologie der Universität Hamburg).

Publikationen:

Originalarbeiten

- 1) Kalthoff H, Röder C, Schewe K, Schmiegel W, Thiele HG, Heimann B, Bading H, Schramm K, Moelling K (1989) Analysis of c-raf oncogene expression in gastrointestinal tumor cells. Haematol Blood Transfus. 1989;32:436-40.
- 2) Zöllner N, Zoller WG, Spengel F, Weigold B, Schewe CK (1991) The spontaneous course of small abdominal aortic aneurysms. Aneurysmal growth rates and life expectancy. Klin Wochenschr. 69: 633-639
- 3) Rauh G, Schuster H, Schewe CK, Stratmann G, Keller C, Wolfram G, Zöllner N (1993) Independent mutation of arginine (3500) => glutamine associated with familial defective apolipoprotein B-100. J Lipid Res 34:799-805
- 4) Zoller WG, Schweikart HP, Schewe CK, Spengel FA, Zöllner N (1993) Langjährige Verlaufsbeobachtung kleiner Bauchaortenaneurysmen. Der Kassenarzt 33:44-48
- 5) Schewe CK, Schuster H, Hailer S, Wolfram G, Keller C, Zöllner N (1994) Identification of defective binding of low density lipoprotein by the U937 proliferation assay in German patients with familial defective apolipoprotein B-100. Eur J Clin Invest 24: 36-41
- 6) Schewe CK, Schweikart HP, Hammel G, Spengel FA, Zöllner N, Zoller WG (1994) Influence of selective management on the prognosis and the risk of rupture of abdominal aortic aneurysms. Clin Investig 72:585-591
- 7) Schewe CK, Kellner H (1996) Rapidly progressive seronegative spondylarthropathy with atlantodental subluxation in a patient with moderately advanced HIV-infection. Clin Exp Rheum 14:83-85
- 8) Meng QH; Pajukanta P; Ilmonen M; Schuster H; Schewe CK; Andersson LC; Tikkanen MJ (1996) Analysis of novel apolipoprotein B mutations using a modified U937 cell line LDL binding assay Clinica chimica acta; international journal of clinical chemistry: 256 (1); p. 27-36
- 9) Schmidt HHJ, Stuhmann M, Shamburek R, Schewe CK, Ebhardt M, Zech LA, Büttner C, Wendt M, Beisiegel U, H. Brewer B Jr., Manns MP (1998) Delayed Low Density Lipoprotein (LDL) Catabolism Despite a Functional Intact LDL-Apolipoprotein B Particle and LDL-

Receptor in a Subject with Clinical Homozygous Familial Hypercholesterolemia The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 6 2167-2174

- 10) Schmidt HH-J, Shamburek R, Schewe CK, Stuhmann-Spangenberg M, Zech LA, Büttner C, Beisiegel U, Brewer Jr HB, Manns MP (1997) Delayed LDL catabolism despite a functional intact LDL-apolipoprotein B particle and LDL-receptor in a subject with homozygous familial hypercholesterolemia. J Clin Invest.
- 11) Horstkotte MA, Sobottka I, Schewe CK, Schäfer P, Laufs R, Rüscher-Gerdes S, Niemann S (2001) Mycobacterium microti Llama-type infection presenting as pulmonary tuberculosis in a human immunodeficiency virus-positive patient. J Clin Microbiol 39:406-407
- 12) Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A, Kroidl Abogner JR, Spengler U, Rockstroh JK (2005) Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. Journal of Viral Hepatitis 12: 207–211
- 13) Schewe CK (2005) Umstrittenes Management der akuten HIV-Infektion. Im Frühstadium antiretroviral behandeln – ja oder nein. MMW-Fortschritte der Medizin 147 Sonderheft 1: 322-324
- 14) Metzner KJ, Rauch P, Walter H, Boesecke B, Zöllner B, Jessen H, Schewe K, Fenske S, Gellermann H, Stellbrink HJ (2005) Detection of minor populations of drug-resistant HIV-1 in acute seroconverters AIDS 19 (16):1819-1825, 2005.
- 15) Schewe CK, Maserati R, Wassmer G, Adam A, Weitner L (2006) Improved lipid profiles and maintenance of virologic control in heavily pre-treated patients switching from stavudine to tenofovir. Clin Infect Dis: 42:145–7.
- 16) Schewe CK, Maserati R, Wassmer G, Adam A, Weitner L (2006) Reply to Manfredi. Clin Infect Dis: 42:1347–8
- 17) Vogel M, Nattermann J, Baumgarten A, Klausen G, Bieniek B, Schewe K, Jessen H, Boesecke C, Rausch M, Lutz T, Fenske S, Schranz D, Kümmerle T, Schuler C, Theisen A, Mayr C, Seidel T, Rockstroh JK (2006) Pegylated interferon-alfa for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antiviral Therapy: 11(8):1097-101
- 18) Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years AIDS 21(10):1273-81.
- 19) Nattermann J, Vogel M, Berg T, Danta M, Axel B, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grünhage F, Rausch M, Nischalke HD, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U; Kompetenznetz HIV/AIDS. (2007) Effect of IL-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in HIV co-infected patients. Hepatology 46(4):1016-25
- 20) Pulido F, Estrada V, Baril JG, Logue K, Schewe K, Plettenberg A, Duiculescu D, Yau L, Vavro C, Lim ML, Pharo C (2009) Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks. HIV Clin Trials;10(2):76–87

- 21) Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H and the Prime-DAG and Ac DAG Study Groups (2009) Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. *Eur J Med Res* 14:277-283
- 22) Schewe K, Noah C, Sirma H, Schmiedel S, Lunzen J, Rockstroh KJ, Oliver Schildgen O (2010) Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report. *Viruses* 2010, 2: 1564-1570
- 23) Knechten H, Stephan C, Mosthaf FA, Jaeger H, Lutz T, Cargnico A, Stoehr A, Koeppel S, Mayr C, Schewe K, Wolf E, Wellmann E, Tappe A (2010) Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients. *Infection*. 2010 Apr;38(2):108-16.
- 24) Knechten H, Stephan C, Mosthaf FA, Jaeger H, Carganico A, Lutz T, Schewe K, Mayr C, Wolf E, Wellmann E, Tappe A (2011) The Rainbow Cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pretreated but protease inhibitor (PI)-naïve HIV-infected patients. *European Journal of Medical Research* Vol 16: pp93-100
- 25) Nattermann J, Vogel M, Nischalke HD, Danta M, Mauss S, Stellbrink HJ, Baumgarten A, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Naumann U, Lutz T, Rausch M, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U (2011) Genetic Variation in IL28B and Treatment-Induced Clearance of Hepatitis C Virus in HIV-Positive Patients With Acute and Chronic Hepatitis C. *J Infect Dis*. 2011 Jan 21
- 26) Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, Rausch M, Hower M, Ulmer A, Wolf E, Lorenzen T, Arendt G, Jansen K; the Competence Network for HIV/AIDS (2011) Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. *Infection* 39: pp3-12
- 27) Zoufaly A, an der Heiden M, Marcus U, Hoffmann C, Stellbrink H, Voss L, van Lunzen J, Hamouda O; ClinSurv Study Group (2012) Late Presentation for HIV diagnosis and care in Germany. *HIV Med*. 2012 Mar;13(3):172-81.
- 28) Stoll M, Kollan C, Bergmann F, Bogner J, Faetkenheuer G, Fritzsche C, Hoepfer K, Horst HA, van Lunzen J, Plettenberg A, Reuter S, Rockstroh J, Stellbrink HJ, Hamouda O, Bartmeyer B (2011) ClinSurv Study Group. Calculation of direct antiretroviral treatment cost savings by using generics in the German HIV ClinSurv cohort. *PLoS One*. Vol 6(9):e23946. Epub 2011 Sep 9.
- 29) Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, Wolf E, Mayr C, Jaeger H, Pfaff H, Dupke S, Neumann A (2013) Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study. *Eur J Health Econ*, Vol14, pp 799-808
- 30) Robertson K, Bayon C, Molina JM, McNamara P, Resch C, Munoz-Moreno JA, Kulasegaram R, Schewe K, Burgos-Ramirez A, De Alvaro C, Cabrero E, Guion M, Norton M, van Wyk J (2014) Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. *AIDS Care*. Vol

Buchbeiträge

- 1) Kalthoff H, Röder C, Schewe CK, Schmiegel W, Thiele H-G, Heimann B, Bading H, Schramm K, Moelling K (1989) Analysis of c-raf-oncogene expression in gastrointestinal tumor cells. In: Neth RD et al (eds) Modern trends in human leukemia VIII, Springer Verlag Heidelberg: 436-440
- 2) Schewe CK (2004) Management der primären HIV-Infektion. In HIV und AIDS: Bedrohungen und Lösungen, Chancen und Herausforderungen. Editor C. Hoffmann, H. Jäger. AIDS und Infektionen in Klinik und Praxis, pp 123-125
- 3) Schewe CK (2004) Aktuelle Studien zu Tenofovir und Emtricitabine. In HIV und AIDS: Bedrohungen und Lösungen, Chancen und Herausforderungen. Editor C. Hoffmann, H. Jäger. AIDS und Infektionen in Klinik und Praxis, pp 147
- 4) Schewe CK (2008) Massgeschneiderte Therapie des Backbones. In AIDS 2008 – PräventionsBotschaften, MenschenRechte, TherapieFortschritte. Editor C. Hoffmann, H. Jäger, pp 6-7

Abstracts/Poster

- 1) Kalthoff H, Röder C, Schewe CK, Schmiegel W, Klöppel G, Thiele HG (1987) Analysis of oncogene expression in tumor cells of the pancreas and the stomach. Oral presentation at the 8th annual congress of the International Society for Oncodevelopmental Biology Meeting (ISOBM) in Ste. Foy, Kanada 1987.
- 2) Klöppel G, Maillet B, Schewe CK, Kalthoff H, Schmiegel WH (1989) Immunocytochemical detection of epidermal growth factor receptors (EGFR) and transferrin receptors (TR) on normal, inflamed and neoplastic pancreatic tissue. Pankreas 4: 623
- 3) Bauriedel G, Windstetter U, Schewe CK, Mertsching H, von Pölnitz A, Kandolf R, Höfling B (1990) Enhanced in vitro motility of smooth muscle cells cultivated from human restenotic plaques. Arteriosclerosis 10: 845a
- 4) Windstetter U, Bauriedel G, Schewe CK, Mertsching H, von Pölnitz A, Kandolf R, Höfling B (1990) Cell culture of human coronary plaques obtained by intraoperative and percutaneous atherectomy. Arteriosclerosis 10: 845a
- 5) Schewe CK, Bauriedel G, Windstetter U, Jahn L, Höfling B (1990) Differential cytokeratin expression in cultured human smooth muscle cells from primary stenosing and restenosing plaques ? Poster presentation at the 38th annual meeting of the European Tissue Culture Society in London, Great Britain, 1990.
- 6) Bauriedel G, Schewe CK, Windstetter U, Brandl R, Becker HM, Jahn L, Höfling B (1990) Unterschiedliche Zytokeratin-Expression in kultivierten glatten Muskelzellen aus primär- und restenosierendem Plaque-Gewebe ? Vasa Suppl 32: 216-219
- 7) Bauriedel G, Windstetter U, Schewe CK, Überfuhr P, Kandolf R, Höfling B (1990) Zellkultivierung von humanem Plaque-Gewebe nach perkutaner und intraoperativer koronarer Atherektomie. Vasa Suppl 32: 350-352
- 8) Bauriedel G, Windstetter U, Plas E, Schewe CK, Kandolf R, Höfling B (1990) Motilität kultivierter Gefäßwandmyozyten aus perkutan atherektomierten Primär- und Restenose-Plaques. Vasa Suppl 32: 353-355
- 9) Zöllner N, Schewe CK, Gresser U (1991) Periaortale Fibrose bei autoptisch ungeklärter Systemerkrankung. Ultraschall in Klinik und Praxis 6: 143
- 10) Schewe CK, Bogner JR, Fabricius PG, Zoller WG (1991) Rezidivierende Nierenabszesse bei HIV-Infektion. Ultraschall in Klinik und Praxis 6: 143
- 11) Zoller WG, Schewe CK, Spengel F, Zöllner N (1991) Zum Spontanverlauf kleiner, nicht operierter Bauchortenaneurysmen. Ultraschall in Klinik und Praxis 6: 212
- 12) Heinrich B, Zoller WG, Zietz C, Schewe CK, Spengel FA, Zöllner N (1991) Aszites als einziges Symptom einer Chlamydien-Peritonitis. Ultraschall in Klinik und Praxis 6: 235

- 13) Schewe CK, Hailer S, Schuster H, Keller C, Wolfram G, Zöllner N (1992) Anwendung einer Lymphozyten-Proliferations-Assays zur Identifikation von Patienten mit Familiärem Apo B-100 Defekt (FDB). *Klin Wochenschr* 69 (Suppl. XXIII): 74
- 14) Zoller WG, Schewe CK, Schweikart HP, Spengel F, Zöllner N (1992) 15-jährige Verlaufsbeobachtung kleiner Bauchortenaneurysmen. *Klin Wochenschr* 69 (Suppl. XXIII): 147
- 15) Schewe CK, Schuster H, Hailer S, Keller C, Wolfram G, Zöllner N (1992) Detection of defective LDL-binding by determination of LDL-dependent proliferation of U937 cells. Poster presentation at the 59th European Atherosclerosis Society Congress in Nice, France, 1992.
- 16) Schewe CK, Schweikart HP, Spengel F, Zoller WG (1992) Spontanverlauf von kleinen, asymptomatischen Bauchortenaneurysmen (BAA). *Ultraschall in Klinik und Praxis* 7: 168
- 17) Schewe CK, Zoller WG (1992) Lumbago - Ein seltenes Symptom des wachsenden Bauchortenaneurysmas. *Ultraschall in Klinik und Praxis* 7: 205
- 18) Schewe CK, Zoller WG, Schweikart HP, Spengel F, Zöllner N (1992) Einflussfaktoren auf den Spontanverlauf von kleinen, asymptomatischen Bauchortenaneurysmen (BAA). *Vasa Suppl* 35: 50-52
- 19) Schewe CK (1991) A proliferation assay with U 937 cells for the detection of familial defective apolipoprotein B-100. Oral presentation at the first international workshop on familial defective apo B-100 in Munich, Germany, 1991. Published in: Schuster H, Humphries S, Rauh G, Keller C. First international workshop on familial defective apo B-100. *Clin Investig* 1992; 70: 961-964
- 20) Degen O, Lunzen J van, Schewe CK, Verbeck A, Stellbrink HJ (1999) Therapieintensivierung durch Abacavir. *European Journal of Medical Research* Vol 4 Suppl.1:34-35
- 21) Degen O, Lunzen J van, Verbeck A, Hoffmann C, Schewe CK, Stellbrink HJ (1999) Rescue-Therapie mit Ritonavir und Nelfinavir. *European Journal of Medical Research* Vol 4 Suppl.1:54
- 22) Eggers C, Schewe CK, Lunzen J van, Verbeck A, Stellbrink HJ (1999) Verzögerte Eliminationskinetik von HIV im Liquor bei HIV-Encephalopathie. *European Journal of Medical Research* Vol 4 Suppl.1:57
- 23) Degen O, van Lunzen J, Schewe CK, Verbeck A, Stellbrink HJ (1999) Early intensification of stable background antiretroviral therapy with abacavir. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection. Abstract 560 pp122-123
- 24) Degen O, Lunzen J van, Schewe K, Stellbrink HJ (2000) Divergent induction followed by long term convergent antiretroviral therapy in HIV positive patients with high risk of therapy failure. *AIDS* Vol 14 Suppl 4 pp 21

- 25) Schewe K, Adam A, Weitner L (2003) Analyse klinischer, immunologischer und virologischer Parameter bei 72 HIV-infizierten Patienten nach Umstellung von Stavudine auf Tenofovir. Eur J Med Res Vol 8 Suppl 1 pp36
- 26) Schewe K, Adam A, Weitner L (2003) Wirksamkeit und Verträglichkeit von Efavirenz in der klinischen Praxis – Eine Analyse von 206 mit Efavirenz (EFV) behandelten Patienten einer HIV-Schwerpunktpraxis. Eur J Med Res Vol 8 Suppl 1 pp30
- 27) Jaeger H, Koegl C, Wolf E, Jessen H, Schewe C, Goelz J, Hoffmann C, Fenske S, Knechten H (2003) Prime DAG – Erste Ergebnisse zu 91 Patienten mit primärer HIV-Infektion. Eur J Med Res Vol 8 Suppl 1 pp38-39
- 28) Vogel M, Bieniek B, Jessen H, Schewe CK, Lutz T, Kroidl A, Bogner J, Spengler U, Rockstroh JK (2003) Treatment of acute hepatitis C infection in HIV-infected patients – First results from a German multicenter study. Eur J Med Res Vol 8 Suppl 1 pp28
- 29) Schewe CK, Adam A, Weitner L, Meyer T (2003) Evaluation of efficacy and safety of tenofovir DF (TDF) after switch from stavudine (D4T) in 93 chronically HIV-1 infected patients. European AIDS Conference 2003 Warsaw Poster 9.8/2, pp83
- 30) Vogl M, Bieniek B, Jessen H, Schewe CK, Lutz T, Kroidl A, Bogner J, Spengler U, Rockstroh J (2003) The treatment of acute hepatitis C infection in HIV-coinfected patients – a retrospective analysis of 8 cases in a multicenter setting. European AIDS Conference 2003 Warsaw Poster 13.2/6 pp96-97
- 31) Vogel M, Bieniek B, Jessen H, Schewe CK, Lutz T, Baumgarten A, Kroidl A, Bogner J, Spengler U, Rockstroh J.K. The treatment of acute Hepatitis C infection in HIV-infected patients – a retrospective analysis of 10 cases in a multicenter setting. World AIDS Conference 2004 Bangkok Poster MoPeB3328 pp 82
- 32) Schewe CK, Adam A., Goey H, Meyer T, Weitner L. Antiviral activity of Abacavir in combination with Tenofovir as backbone of HAART in heavily pretreated patients. World AIDS Conference 2004 Bangkok Poster B11 008
- 33) Jaeger H, Jessen H, Goetzenich A, Koegl C, Schewe CK, Rausch M, Wolf E, Goelz J, Knechten H. Primary HIV-infection: clinical symptoms are correlated with early outcome in the non-treatment group. World AIDS Conference 2004 Bangkok Poster TuPeB4590 pp 365
- 34) Schewe CK, Adam A, Goey H, Meyer T, Weitner L. Tolerability, virologic and immunologic activity of efavirenz in pre-treated long term HIV-infected patients. Seventh International Congress on Drug Therapy in HIV Infection Glasgow 2004 Poster 58.
- 35) Jessen H, Fenske S, Weitner L, Schewe CK, Glässel F, Gorrhian F, Schneider L, Nakonz T. (2005) Didanosin, Stavudin oder Beides: Optimale Kombinationspartner in einem Efavirenz-Regime? Eine retrospective Datenanalyse. Eur J Med Res 10 Suppl. II Poster 124: pp 75

- 36) Schewe CK, Arribas JJ, DeJesus E, Campo R, Jemsek J, Gallant JE, Gazzard B, Pozniak AL, Lu B, Enejosa J, Cheng A (2005) Die Kombination von Tenofovir-DF (TDF), Emtricitabin (FTC) und Efavirenz (EFV) zeigt ein signifikant besseres Ansprechen als die Kombination Zidvudin/Lamivudin (CBV) und EFV bei antiretroviral nicht vorbehandelten Patienten: Eine Interimsanalyse nach 24 Wochen. Eur J Med Res 10 Suppl. II Poster 158: pp 88
- 37) Wolf E, Kaliebe T, Ranneberg B, Koegl C, Schewe K, Jaegel-Guedes E, Jaeger H (2005) Renal safety of Tenofovir (TDF) in clinical practice – a pooled analysis of two German cohorts. Eur J Med Res 10 Suppl. II Poster 154: pp 87
- 38) Koegl C, Wolf E, Jessen H, Schewe K, Rausch M, Goelz J, Knechten H, Jaeger H (2005) Virus control after early treatment of primary HIV-infection. Eur J Med Res 10 Suppl. II Vortrag 8: pp 27
- 39) Lunzen J van, Schewe K, Kuhlmann B, Hoffmann C, Stoll M, Delfraissy JF (2005) Once daily therapy with tenofovir + didanosine + efavirenz in antiretroviral naive patients – results of the 12 week interim analysis of the TEDDI trial. Eur J Med Res 10 Suppl. II Vortrag 74: pp 54
- 40) Stoll M, Kollan C, Lubach-Ruitman M, Schwarze-Zander C, Schewe K, Weitner L, Rockstroh J, Schmidt RE, Hamouda O, ClinSurv Study Group (2005) Increase of direct costs for highly active antiretroviral treatment (HAART) regimens in the German ClinSurv multicenter cohort. Eur J Med Res 10 Suppl. II Vortrag 76: pp 54-55
- 41) van Lunzen J, Schewe K, Kuhlmann B, Hoffmann C, Stoll M, Dellamonica P, Prazuck T, Benech H, Taburet AM, Delfraissy JF (2005) High rate of virological failure during once daily therapy with tenofovir + didanosine 250mg + efavirenz in antiretroviral naïve patients – results of the 12 week interim analysis of the TEDDI trial. International AIDS conference Rio de Janeiro. TuPp0306
- 42) Schewe K, Noah C, Adam A, Weitner L (2005) Switch to antiretroviral regimens containing Tenofovir (TDF) and Nevirapine (NVP) – A retrospective analysis of efficacy and tolerability. 10th European AIDS Concerence, Dublin. PE7.5/6 pp 68
- 43) Vogel M, Baumgarten A, Klausen G, Lutz T, Mauss S, Theisen A, Wasmuth JC, Rausch M, Schranz D, Cordes C, Hoffmann C, Wyen C, Schewe K, Ummard K, Dupke S, Spengler U, Rockstroh J for the German Hepatitis Group (2005) Predictive factors in the treatment of acute HCV-infection in HIV-positive individuals – interim analysis of a large German multicenter study. 10th European AIDS Concerence, Dublin. PS7/7 pp 21
- 44) Koegl C, Wolf E, Jessen H, Schewe K, Rausch M, Goelz J, Götzenich A, Knechten H, Jäger H and the Prime-DAG and Ac-DAG Study Group (2006) Does early treatment of primary HIV-Infection delay treatment indication? 16th International AIDS Conference, Toronto Poster MoPE0060, pp49
- 45) VOGEL M, NATTERMANN J, BAUMGARTEN A, KLAUSEN G, LUTZ T, MAUSS S, MAYR C, HINTSCHE B, SCHRANZ D, BIENIEK B, STELLBRINK H, SCHULER C, SCHEWE K, UMMARD K, CARGANICO A, ROCKSTROH JK (2006) Treatment of Sexually Transmitted Acute HCV-infection in HIV-positive Individuals. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy Poster H 1060, pp282

- 46) VOGEL M, NATTERMANN J, BAUMGARTEN A, KLAUSEN G, LUTZ T, MAUSS S, MAYR C, HINTSCHE B, SCHRANZ D, BIENIEK B, STELLBRINK H, SCHULER C, SCHEWE K, UMMARD K, CARGANICO A, ROCKSTROH JK (2006) Treatment of Sexually Transmitted Acute HCV-infection in HIV-positive Individuals. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy Poster H 1060, pp282
- 47) Koegl C, Wolf E, Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H, and the Prime-DAG and Ac-DAG study group (2007) No benefit from early treatment in primary HIV-infection. 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007) oral # LB125 pp111
- 48) Stoll M, Kollan C, Oette M, Horst MH, Schewe K, Kuehne A, Hamouda O, ClinsSurv study group (2007) Direct costs for highly active antiretroviral treatment (HAART) regimens in the German ClinSurv multicenter cohort 1996-2006. Eur J of Med Res 12 Suppl II pp10-11
- 49) Noah C, Korn K, Meyer T, Schewe CK, Fenske S, Plettenberg A, Hoffmann C, Stellbrink HJ (2007) High extent of clustering of patients with HIV seroconversion in Hamburg in 2005-2006. Eur J of Med Res 12 Suppl II pp26
- 50) Nattermann J, Vogel M, Berg T, Danta M, Baumgarten A, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grünhage F, Rausch M, Nischalke HD, Schewe K, Bieniek B, Haerter G, Spengler U, Rockstroh J Kompetenznetz HIV/AIDS (2007) Effect of IL-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C I HIV co-infected patients. Eur J of Med Res 12 Suppl II pp70
- 51) Knechten H, Carganico A, Glaessel F, Jaeger H, Knecht G, Koeppe S, Lutz T, Mayr C, Mosthaf F, Schewe K, Schuler C, Stephan C, Wolf E, Steinmüller J, Waesle B, Trappe A, Wellmann E (2007) The rainbow cohort: Saquinavir/r is effective and well tolerated in antiretroviral therapy (ART)-naïve patients initiating treatment with saquinavir 500mg film-coated tablets – 24 week interim results from Germany. Eur J of Med Res 12 Suppl II pp80
- 52) Schewe CK, Fenske S, Schnaitmann E, Trein A, Ranneberg B, Gallo L, Mertenskoetter T (2007) Use of Tenofovir DF in experienced patients – 96 weeks data from a German outpatient cohort. Eur J of Med Res 12 Suppl II pp82
- 53) Schewe K, Fenske S, Weitner L, Adam A, Buhk T, Stellbrink HJ (2007) Incidence of clinically significant renal events among patients treated with Tenofovir (TDF) in comparison to patients who never received TDF as part of their ART. Results of an observational cohort study. Eur J of Med Res 12 Suppl II pp85
- 54) Schewe K, Adam A, Goldbach J, Weitner L (2007) Duration of NNRTI treatment after switch to a first Nevirapine or Efavirenz-containing regimen. An observational cohort analysis. Eur J of Med Res 12 Suppl II pp86
- 55) Fenske S, Postel N, Stoehr A, Lauenroth-Mai E, Eckert M, Reeb I, Schewe K (2007) Didanosine in a large and unselected German patient population: Efficacy, safety and clinical outcome. Eur J of Med Res 12 Suppl II pp87
- 56) Schewe K, Fenske S, Schmeisser N, Weitner L, Adam A, Buhk T, Stellbrink HJ, Hansen S, Gellermann H (2007) Effect of switch from lopinavir soft gel capsules to Lopinavir meltrex formulation on gastrointestinal side effects, quality of life, lipid, virologic and immunologic parameters. Eur J of Med Res 12 Suppl II pp88

- 57) Poggensee G, Kücherer C, Werning J, Bartmeyer B, Fleischhauer C, Braun P, Cordes C, Jessen H, Klausen G, Schewe K, Stoll M, van Lunzen J, Hamouda O (2007) Antiretroviral therapy of patients infected with drug resistant HIV-strains: Analysis of the composition of the first line regimens in patients with a documented date of HIV-infection in Germany. Eur J of Med Res 12 Suppl II pp106
- 58) Stephan C, Carganico A, Glaessel F, Jaeger H, Knecht G, Koeppe S, Lutz T, Mayr C, Mosthaf F, Mueller M, Schewe K, Schuler C, Wolf E, Tappe A, Waesle B, Wellmann E, Knechten H (2007) Antiretroviral tolerability and efficacy after switch to saquinavir 500mg film-coated tablets in protease inhibitor (PI) -experienced patients: 24 week interim analysis of the German rainbow cohort. EACS Madrid P7.3/23
- 59) Schewe K, Christ H, Adam A, Weitner L, Stellbrink H-J (2007) Incidence of clinically significant renal events among patients treated with tenofovir (TDF) in comparison to patients who never received TDF as part of their ART. Results of an observational cohort study. EACS Madrid P9.1/03
- 60) Stellbrink HJ, Schewe K, Hoffmann C, Wolf E (2008) Is there a harmless level of plasma viremia in untreated HIV-infection? CD4+ T cells in the long-term follow up of elite controllers and controls. CROI 2008 Boston #351 pp180
- 61) Lorenzen T, Walther I, Bogner JR, van Lunzen J, Schuler C, Fätkenheuer G, Gute P, Schewe CK, Köppe S, Schranz D, Horst HA, Stoehr A, Plettenberg A (2009) Treatment of HIV-infected patients with a HAART regimen containing Enfuvirtide and a "second generation" protease inhibitor. Eur J Med Res 14 (Suppl I) #404 pp59
- 62) Van Lunzen J, Fätkenheuer G, Lutz T, Klauke S, Mauss S, Schewe CK, Knechten H, Braun P, Gallo L, Ranneberg B (2009) Efficacy and safety of TDF/FTC-containing first line HAART in clinical practice – two year data from the German outpatient cohort. Eur J Med Res 14 (Suppl I) #416 pp65
- 63) Vogel M, Baumgarten A, Ummard K, Rausch M, Schewe K, Mayr C, Schranz D, Theisen A, Jessen H, Fenske S, Lutz T, Bieniek B, Schuler C, Kümmerle T, Mauss S, Hintsche B, Behrendt D, Gözl J, Rockstroh KJ (2009) The definition "acute" does not influence SVR in HIV-positive individuals treated with pegylated interferon+/- ribavirin after acute HIV-infection. Eur J Med Res 14 (Suppl I) #455 pp82
- 64) Zoufaly A, Hertling S, Fätkenheuer G, Lutz T, Klauke S, Stoehr A, Mauss S, Schewe K, Ranneberg B, van Lunzen J (2009) Combination therapy with tenofovir DF (TDF)/emtricitabine (FTC) and Efavirenz leads to sustained and favourable responses in a large outpatient cohort (German TRUVADA cohort). 5th IAS Conference Cape Town #MOPEB058 pp51
- 65) Vogel M, Voigt E, Henke J, Goey H, Baumgarten A, Bilzer M, Naumann U, Gözl J, Schewe K, Mauss S, Tossing G, Hoffmann C, Rockstroh JK, Klinische Arbeitsgemeinschaft AIDS Deutschland (KAAD) (2009) Efficacy of modern pegylated interferon / ribavirin combination therapy in the treatment of chronic HCV infection in HIV co-infected individuals. 12th EACS Cologne, Germany; #P 13.2/3
- 66) Stellbrink HJ, Schewe K, Vogel M, Hoffmann C, Noah C (2010) Incidence, genotype distribution and prognosis of sexually transmitted acute hepatitis C in a cohort of HIV-infected patients. CROI 2010 San Francisco #645 pp308

- 67) Stellbrink HJ, Schewe K, Schneider A, Mohrmann G, Noah C (2011) Korrelation von P1NP als Marker der Knochenformation mit der Dauer einer Tenofovir (TDF) –basierten Therapie. Deutsch Österreichischer AIDS Kongress V69
- 68) Stellbrink HJ, Schewe K, Schneider A, Mohrmann G, Noah C (2011) Proximal renal-tubuläre Dysfunktion (PRTD) unter Tenofovir: Einfluss auf Nierenfunktion und Reversibilität. Deutsch Österreichischer AIDS Kongress V71
- 69) Kollan C, Bartmeyer B, Bergmann F, Bogner J, Fritzsche C, Gillor D, Horst HA, Kühne A, Plettenberg A, Reuter S, Schewe K, Stoll M, van Lunzen J, Wasmuth JC, Hamouda O and the ClinSurv Study Group (2011) Antiretroviral treatment outcome in a large prospective German HIV cohort study – how much virus is still around. Deutsch Österreichischer AIDS Kongress PW49
- 70) Stellbrink HJ, Schewe K, Vogel M, Boesecke C, Noah C (2011) Akute Hepatitis C bei HIV+ MSM: Hohe Remissionsraten aber hohes Reinfektionsrisiko. Deutsch Österreichischer AIDS Kongress PW98
- 71) Van Lunzen J, Gorrhian D, Wünsche T, Dupke S, Gute P, Schewe K, Ranneberg B (2011) Wirksamkeit und Verträglichkeit von Darunavir/r (DRV/r) 600/100mg bid bei antiretroviral vorbehandelten Patienten – 48 Wochen Daten aus einer deutschen Kohorte. Deutsch Österreichischer AIDS Kongress PW141
- 72) Plettenberg A, Brockmeyer NH, Haastert B, Dupke S, Schewe K, Rausch M, Hower M, Arendt G, Skaletz-Rorowski A, Jansen K, and the Competence Network for HIV/AIDS (2011) Impact of timing HAART initiation on immune status and clinical course in the cohort of the German Competence Network for HIV/AIDS. Deutsch Österreichischer AIDS Kongress PW164

Letters

- 1) Vielhauer V, Schewe CK, Schlöndorff V (1998) Bilateral thrombosis of the internal jugular veins with spasmodic torticollis in a patient with acquired immunodeficiency syndrome and disseminated cytomegalovirus infection. *J Infect* 37;90-91
- 2) Schildgen O, Schewe CK, Vogel M, Daumer M, Kaiser R, Weitner L, Matz B, Rockstroh JK (2004) Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. *AIDS*. 2004 Nov 19;18(17):2325-2327
- 3) Hoffmann C, Schewe K, Stellbrink HJ, Weitner L (2011) "Comment on: Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naïve HIV-1 patients: the ARTEN Trial. *Antiviral Therapy*, 16(3):339-48.